Speciality: Oncology
Description:
A warm welcome to all the medical professionals in this crucial session on understanding the current scenario of blood cancer. Genomic testing and advancements in diagnosis and treatment have ushered in a new era of personalized medicine for hematological malignancies. The shift from a "one-size-fits-all" approach to tailored therapies based on a patient's unique genetic makeup has significantly improved outcomes. Cutting-edge technologies, such as Next-Generation Sequencing (NGS), allow for a comprehensive profiling of tumors, identifying specific mutations and genetic abnormalities that drive the disease, which is essential for accurate classification and prognosis.
The integration of these genomic insights into clinical practice has led to the development and approval of a new generation of targeted therapies and immunotherapies, including CAR T-cell therapy and bispecific antibodies. These treatments are designed to attack cancer cells with precision, often leading to better efficacy and reduced side effects compared to traditional chemotherapy. The ability to monitor treatment response and detect residual disease with greater sensitivity through genomic testing further enhances the effectiveness of these advanced therapeutic strategies, improving the chances of long-term remission and a higher quality of life.
Therefore, get an overall knowledge of the current and future landscape of blood cancer diagnosis and treatment. Listen to the insights shared by Dr. Abhay Bhave, a leading expert in the field, absorb the shared knowledge on genomic advancements, and follow Hidoc for more such insightful webinar sessions.
See More Webinars @ Hidoc Webinars
1.
Extended Maintenance with Imatinib Enhances Disease-Free Survival in High-Risk GIST.
2.
A higher risk of chemotherapy-induced peripheral neuropathy is associated with a deficiency in vitamin D prior to treatment.
3.
Nearly 4 million lung cancer deaths averted and 76 million years of life gained due to tobacco control in US
4.
Targeted Combination Shows Promise in Metastatic Kidney Cancer
5.
Through Consolidation Durvalumab, Limited-Stage SCLC Receives a New Standard of Care.
1.
Predicting Incidental Prostate Cancer in BPH Surgery Patients
2.
Unveiling the Hidden Dangers of Hand Cancer: How to Protect Yourself
3.
Late Effects of Immunotherapy in Chronic Melanoma Survivorship with Repurposed Drugs
4.
Beyond the Human Eye: How AI Is Redefining Brain Cancer Diagnosis Through Advanced Imaging
5.
The Converging Frontiers of Radiation Oncology and Systemic Therapies by 2025
1.
International Lung Cancer Congress®
2.
Future NRG Oncology Meeting
3.
Genito-Urinary Oncology Summit 2026
4.
ISMB 2026 (Intelligent Systems for Molecular Biology)
5.
Annual International Congress on the Future of Breast Cancer East
1.
Virtual Case Study on Deep Vein Thrombosis (DVT) - An Initiative by Hidoc Dr.
2.
Revolutionizing Treatment of ALK Rearranged NSCLC with Lorlatinib - Part VI
3.
Efficient Management of First line ALK-rearranged NSCLC - Part II
4.
An Eagles View - Evidence-based discussion on Iron Deficiency Anemia
5.
Treatment Paradigm for Patients with R/R Adult B-cell ALL- Expert Discussions
© Copyright 2026 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation